SCHEMBL6887450

SCHEMBL6887450

CCc1nc2ccc(N3CCN4CCC3CC4)cc2c(=O)n1CC1CC1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 3/20 0.43
KCNH2 Q12809 3/20 0.36
HTR3A P46098 3/20 0.35
CHRNA1 P02708 1/20 0.35
CHRNB2 P17787 1/20 0.35
CHRNB4 P30926 1/20 0.35
CHRNA3 P32297 1/20 0.35
CHRNA4 P43681 1/20 0.35
CYP2D6 P10635 2/20 0.35
HDAC1 Q13547 2/20 0.35
HDAC11 Q96DB2 2/20 0.35
HDAC8 Q9BY41 2/20 0.35
HDAC6 Q9UBN7 2/20 0.35
HDAC2 Q92769 1/20 0.35
CNR2 P34972 2/20 0.34
GHSR Q92847 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6890552 0.93 CHRNA7 (0.40) CHRNA7KCNH2HTR3ACNR2
SCHEMBL6888096 0.89 CHRNA7 (0.44) CHRNA7KCNH2HTR3ACHRNA1CHRNB2
SCHEMBL6887544 0.87 CHRNA7 (0.43) CHRNA7KCNH2HDAC1HDAC11HDAC8
SCHEMBL6887861 0.85 CHRNA7 (0.46) CHRNA7KCNH2HTR3ACHRNA1CHRNB2
SCHEMBL6887453 0.84 CHRNA7 (0.44) CHRNA7KCNH2HTR3ACHRNA1CHRNB2
SCHEMBL6888588 0.84 CHRNA7 (0.40) CHRNA7KCNH2HDAC1HDAC11HDAC8
SCHEMBL6888343 0.84 CHRNA7 (0.40) CHRNA7KCNH2HTR3ACHRNA1CHRNB2
SCHEMBL6889309 0.82 CHRNA7 (0.44) CHRNA7KCNH2HTR3ACHRNA1CHRNB2
SCHEMBL6887911 0.81 AVPR1B (0.43)
SCHEMBL6887587 0.81 CHRNA7 (0.38) CHRNA7HDAC1HDAC11HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8841289-B2 Heterocyclic derivatives MERCK SHARP & DOHME B.V. (US) 2014-09-23 US disclosed
US-8841289-B2 Heterocyclic derivatives MERCK SHARP & DOHME B.V. (US) 2014-09-23 US disclosed
US-8841289-B2 Heterocyclic derivatives MERCK SHARP & DOHME B.V. (US) 2014-09-23 US disclosed
US-20120208796-A1 HETEROCYCLIC DERIVATIVES ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2012-08-16 US disclosed
US-20120208796-A1 HETEROCYCLIC DERIVATIVES ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2012-08-16 US disclosed
US-20120208796-A1 HETEROCYCLIC DERIVATIVES ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2012-08-16 US disclosed
WO-2011045258-A1 CONDENSED AZINE - DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE ACETYLCHOLINE RECEPTOR N.V. ORGANON (NL) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208796-A1 HETEROCYCLIC DERIVATIVES CHRNA5, CHRM5, CHRNA7 CHRNA7 3/4885KCNH2 728/4885HTR3A 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.